

Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcorn Robert C. Millonig Lawrence B. Bugaisky Donald J. Featherstone Michael V. Messinger Judith U. Kim Timothy J. Shea, Jr. Patrick E. Garrett Heidi L. Kraus Edward W. Yee Albert L. Ferro\* Donald R. Banowit Peter A. Jackman Molly A. McCall Teresa U. Medler Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Call Thomas C. Fiala Brian J. Del Buono Virgil Lee Beaston Kimberly N. Reddick Theodore A. Wood Elizabeth J. Haanes Bruce E. Chalker Joseph S. Ostroff Frank R. Cottingham Christine M. Lhuller Rae Lynn Prengaman Jane Shershenovich\* Lawrence J. Carroll\* George S. Bardmesser Daniel A. Klein\* Jason D. Eisenberg Michael D. Specht Andrea J. Kamage Tracy L. Muller\* Jon E. Wright.\*

LuAnne M. Yurick\* John J. Figueroa

Ann E. Summerfield Tiera S. Coston\* Aric W. Ledford\* Registered Patent Agents\* Karen R. Markowicz Nancy J. Leith Helene C. Carlson

Namer J. Hardwith
Helene C. Carlson
Gaby L. Longsworth
Matthew J. Dowd
Aaron L. Schwartz
Mary B. Tung
Katrina Y. Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Timothy A. Doyle
Jennifer R. Mahalingappa

Teresa A. Colella Jeffrey S. Lundgren Victoria S. Rutherford Eric D. Hayes

Of Counsel Kenneth C. Bass III Evan R. Smith

\*Admitted only in Maryland \*Admitted only in Virginia •Practice Limited to Federal Agencies

November 25, 2003

WRITER'S DIRECT NUMBER: (202) 772-8673
INTERNET ADDRESS: JCOVERT@SKGF.COM

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Group Art Unit 1614

Da.

U.S. Utility Patent Application

Appl. No.: 10/644,783; Filed: August 21, 2003

For: Sodium Channel Blocker Compositions and the Use Thereof

Inventor:

Nancy C. LAN

Our Ref:

1483.0370003/JMC/THN

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Information Disclosure Statement;
- 2. Form PTO-1449 (20 pages);
- 3. Copies of cited documents AS6; AR8; AS11; AS13; AT13; AT14; AT16; AS19; AT19; and AR20; and
- 4. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox PLLC. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com

Commissioner for Patents November 25, 2003 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

John M. Covert

Attorney for Applicant Registration No. 38,759

**Enclosures** 

::ODMA\MHODMA\SKGF\_DC1;202222;1



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Nancy C. LAN

Appl. No.: 10/644,783

Filed: August 21, 2003

For: Sodium Channel Blocker

Compositions and the Use Thereof

Confirmation No.: 6918

Art Unit: 1614

Examiner: To Be Assigned

Atty. Docket: 1483.0370003/JMC/THN

## Information Disclosure Statement

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of documents AS6, AR8, AS11, AS13, AT13, AT14, AT16, AS19, AT19 and AR20 are provided. Copies of all cited U.S. Patents are not required, as the filing date of this application is after June 30, 2003. Copies of all other documents were cited by or submitted to the Office in an IDS that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 09/971,007, filed October 5, 2001, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

In accordance with 37 C.F.R. § 1.98(a)(3), Applicant's undersigned representative submits the following, in regards to non-English language documents AL2, AN3 and AM4 cited on Form PTO-1449:

Document AL2, French Patent Application No. FR 2 756 738, is in the French language. U.S. Patent No. 6,207,685 B1 claiming priority from FR 2 756 738 is cited as document AJ2.

Document AN3, German Patent Application No. DE 198 02 327 A1, is in the German language. An English language abstract of document AN3 is cited as document AT17.

Document AM4, PCT Patent Application No. WO 99/61408, is in the Spanish language. The corresponding European Patent Application No. EP 1 083 164 is cited as document AL5.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicant has listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicant reserves the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120, 11380G37, 38 (May 19, 1992).

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

Nancy C. LAN Appl. No. 10/644,783

- 3 -

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

John/M. Covert

Attorney for Applicant Registration No. 38,759

Date: Mor. 25, 2003

1100 New York Avenue, N.W. Washington, D.C. 20005-3934

(202) 371-2600

::ODMA\MHODMA\SKGF\_DC1;197844;1



## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783			
APPLICANT Nancy C. LAN				
FILING DATE August 21, 2003	GROUP 1614			

August 21, 2003   1614								
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	4,02	24,175	05/17/1977	Satzinger et al.			12/31/1975
	AB1	4,08	37,544	05/02/1978	Satzinger et al.			04/28/1977
	AC1	4,60	02,017	07/22/1986	Sawyer et al.			02/27/1984
	AD1	4,89	94,476	01/16/1990	Butler et al.			05/02/1988
	AE1	5,02	25,035	06/18/1991	Wallace			10/12/1990
_	AF1	5,17	79,109	01/12/1993	Kamenka et al.			06/21/1990
	AG1	5,23	86,957	08/17/1993	Dostert et al.			01/25/1991
	AH1	5,25	6,669	10/26/1993	Askanazi et al.			08/07/1992
	AI1	5,33	30,515	07/19/1994	Rutecki et al.			06/17/1992
-	AJ1	5,44	16,066	08/29/1995	Varasi et al.			03/22/1994
	_ AK1	5,44	19,692	09/12/1995	Varasi et al.			03/22/1994
				FOREIGN P	ATENT DOCUMENTS			
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1	WO 9	06/40628	12/19/1996	WIPO			Yes No
	AM1	WO 9	7/05102	02/13/1997	WIPO			Yes No
	AN1	WO 9	8/07447	02/26/1998	WIPO			Yes No
	A01	WO 9	8/08842	03/05/1998	WIPO			Yes No
	AP1	WO 9	08/19674 A2	05/14/1998	WIPO			Yes No
		01	THER (Includin	g Author, Ti	tle, Date, Pertinent Pag	ges, etc	:-)	
	Backonja, M., et al., "Gabapentin for the Symptomatic Treatment of Painformatic Treatment of Pai							
	AS	Bennett, G.J., "Neuropathic Pain: An Overview," in Molecular Neurobiology of Pain 9:109-113, Borshook, D., ed., IASP Press, Seattle (1997)						
	Bensimon, G., et al., "A Controlled Trial of Riluzole in Amyotrophic Latera Sclerosis," New England J. Med. 330:585-591, The Massachusetts Medical Societ (1994)							
EXAMINER	EXAMINER DATE CONSIDERED							

<sup>::</sup>ODMA\MHODMA\SKGF\_DC1;197764;1

NOV 2 5 2003 A

FORM PTO-1449

#### INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783			
APPLICANT Nancy C. LAN				
FILING DATE August 21, 2003	GROUP 1614			

					August 21, 2003		1614	
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCU	JMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA2	5,66	50,861	08/26/1997	Jao et al.			05/12/1995
	AB2	5,71	12,277	01/27/1998	Nakamura-Craig et al.			07/15/1996
	AC2	5,74	11,818	04/21/1998	Dimmock			06/07/1995
	AD2	5,89	1,849	04/06/1999	Amstutz et al.			11/07/1997
•	AE2	5,90	5,069	05/18/1999	Borsook et al.			01/26/1998
	AF2	5,94	2,510	08/24/1999	Floyd et al.			06/20/1996
	AG2	6,11	.3,915	09/05/2000	Aoki et al.			10/12/1999
	AH2	6,18	30,624 B1	01/30/2001	Hill			02/25/1999
•	AI2	6,18	37,338 B1	02/13/2001	Caruso et al.			02/22/1999
•	AJ2	6,20	7,685 B1	03/27/2001	Lallement et al.			01/11/1999
	AK2	6,24	2,488 B1	06/05/2001	Bueno et al.			05/09/2000
				FOREIGN P.	ATENT DOCUMENTS			
EXAMINER INITIAL		DOCT	MENT NUMBER	DATE	COUNTRY	CLASS	CHD CLACC	TDANICI ATTO
INTITAL	AL2		2 756 738	06/12/1998	France	CLASS	SUB-CLASS	TRANSLATION X Ye N
	AM2		98/28255	07/02/1998	WIPO			Ye N
	AN2	WO 9	98/19674 A3	07/16/1998	WIPO			Ye N
	A02	WO 9	8/43964	10/08/1998	WIPO			Ye N
	AP2	WO 9	8/47869	10/29/1998	WIPO			Ye N
		07	THER (Includin	g Author, Ti	tle, Date, Pertinent Pag	es, etc	:.)	
	Beydoun, A., "Postherpetic Neuralgia: Role of Gabapentin and Other Treatme AR 2 Modalities," Epilepsia 40(Suppl. 6):S51-S56, Lippincott Williams & Wilki (October 1999)							
	AS	Blinder, B.J., et al., "Advances in Mood Stabilizing Medications," West. J. Med. 169:39-40, BMJ Publishing (1998)						
	Boyce, S., et al., "Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit induced dorsal horn," Neuropharmacology 38:611-623, Pergamon and Elsevier Science Ltd. (May 1999)						B subunit i	
EXAMINER		<u> </u>	<u> </u>			DATE (	CONSIDERED	

EXAMINER DATE CONSIDERE

<sup>::</sup>ODMA\MHODMA\SKGF\_DC1;197764;1



## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE August 21, 2003	GROUP 1614

AC3 6,326,374 B1 12/04/2001 Magnus et al. 06/18/1  AD3 6,326,385 B1 12/04/2001 Wickenden et al. 08/04/2  AE					August 21, 2003 1614				
DOCUMENT NUMBER   DATE   NAME   CLASS   SUB-CLASS   FILING	U.S. PATENT DOCUMENTS								
AA3 6,281,211 B1 08/28/2001 Cai et al. 09/21/2 AB3 6,290,986 09/18/2001 Murdock et al. 06/29/1 AC3 6,326,374 B1 12/04/2001 Magnus et al. 06/18/1 AD3 6,326,385 B1 12/04/2001 Wickenden et al. 03/04/2 AE 6,326,385 B1 12/04/2001 Wickenden et al. 03/04/2 AE AF			DOCT	MENT NUMBER	האתר ה	NAME	CTAGG	CIID - CI A CC	ELLING DATE
AB3 6,290,986 09/18/2001 Murdock et al. 06/29/1 AC3 6,326,374 B1 12/04/2001 Magnus et al. 06/18/1 AD3 6,326,385 B1 12/04/2001 Wickenden et al. 08/04/2 AE	INITIAL	202	_		<del> </del>		CLASS	30B-CHA33	
AC3 6,326,374 B1 12/04/2001 Magnus et al. 06/18/1 AD3 6,326,385 B1 12/04/2001 Wickenden et al. 08/04/2 AE AF AF AG AG AH AI AI AN AK  FOREIGN PATENT DOCUMENTS  EXAMINER INITIAL AD3 W0 99/12537 03/18/1999 WIPO AM3 W0 99/26614 06/03/1999 WIPO AM3 W0 99/37296 07/29/1999 WIPO AD4 W0 99/37296 07/29/1999 WIPO AD5 W0 99/37296 07/29/1999 WIPO AD6 W0 99/37296 07/29/1999 WIPO AD7 WO 99/37296 07/29/1999 WIPO AD8 W0 99/37296 07/29/1999 WIPO AD8 W0 99/37296 07/29/1999 WIPO AD9 W1PO AP3 W0 99/37296 07/29/1999 WIPO AP3	<del></del>		_		<del>                                     </del>				06/29/1998
AD3 6,326,385 B1 12/04/2001 Wickenden et al. 08/04/2  AE					<del>                                     </del>				06/18/1999
AE  AF  AG  AG  AH  AI  AI  AI  AJ  AK   POREIGN PATENT DOCUMENTS  EXAMINER INITIAL  DOCUMENT NUMBER  DATE  COUNTRY  CLASS SUB-CLASS TRANSLI  AL3 W0 99/12537 03/18/1999 WIPO  AM3 W0 99/26614 06/03/1999 WIPO  AN3 DE 198 02 327 A1 07/29/1999 WIPO  AN3 DE 198 02 327 A1 07/29/1999 WIPO  AP3 W0 99/3712 08/12/1999 WIPO  AP3 W0 99/3712 08/12/1999 WIPO  THER (Including Author, Title, Date, Pertinent Pages, etc.)  Brown, C.M., et al., "Neuroprotective properties of lifarizine compared with of other agents in a mouse model of focal cerebral ischaemia," Britis Pharmacol. 115:1425-1432, Stockton Press (1995)  AS 2  Bryans, J.S., and Wustrow, D.J., "3-Substituted GABA Analogs with Central Ne System Activity: A Review," Med. Res. Rev. 19:149-177, John Wiley & Sons, (March 1999)  Buchan, A.M., et al., "AMPA Antagonists: Do They Hold More Promise for Clit					†				08/04/2000
AF AG AG AH AH AI			1 3,52	.0,000 ==	12, \$1, 2002				33, 33, 233
AH AI AJ AJ AK  FOREIGN PATENT DOCUMENTS  EXAMINER INITIAL  AL3 WO 99/12537 03/18/1999 WIPO  AM3 WO 99/26614 06/03/1999 WIPO  AN3 DE 198 02 327 Al 07/29/1999 Germany  AO3 WO 99/37296 07/29/1999 WIPO  AP3 WO 99/39712 08/12/1999 WIPO  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Brown, C.M., et al., "Neuroprotective properties of lifarizine compared with of other agents in a mouse model of focal cerebral ischaemia," Britis Pharmacol. 115:1425-1432, Stockton Press (1995)  Bryans, J.S., and Wustrow, D.J., "3-Substituted GABA Analogs with Central Ne System Activity: A Review," Med. Res. Rev. 19:149-177, John Wiley & Sons, (March 1999)  Buchan, A.M., et al., "AMPA Antagonists: Do They Hold More Promise for Clit	_ •	AF	1	·					
AI AJ AK  FOREIGN PATENT DOCUMENTS  EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLY  AL3 WO 99/12537 03/18/1999 WIPO  AM3 WO 99/26614 06/03/1999 WIPO  AN3 DE 198 02 327 Al 07/29/1999 Germany X  A03 WO 99/37296 07/29/1999 WIPO  AP3 WO 99/37296 07/29/1999 WIPO  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Brown, C.M., et al., "Neuroprotective properties of lifarizine compared with of other agents in a mouse model of focal cerebral ischaemia," Britis Pharmacol. 115:1425-1432, Stockton Press (1995)  AS 2 System Activity: A Review," Med. Res. Rev. 19:149-177, John Wiley & Sons, (March 1999)  Buchan, A.M., et al., "AMPA Antagonists: Do They Hold More Promise for Clit		AG						1	
FOREIGN PATENT DOCUMENTS  EXAMINER INITIAL  DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLY  AL3 WO 99/12537 03/18/1999 WIPO  AM3 WO 99/26614 06/03/1999 WIPO  AN3 DE 198 02 327 Al 07/29/1999 Germany X  AO3 WO 99/37296 07/29/1999 WIPO  AP3 WO 99/37296 07/29/1999 WIPO  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Brown, C.M., et al., "Neuroprotective properties of lifarizine compared with of other agents in a mouse model of focal cerebral ischaemia," Britis Pharmacol. 115:1425-1432, Stockton Press (1995)  AS 3 Bryans, J.S., and Wustrow, D.J., "3-Substituted GABA Analogs with Central Ne System Activity: A Review," Med. Res. Rev. 19:149-177, John Wiley & Sons, (March 1999)  Buchan, A.M., et al., "AMPA Antagonists: Do They Hold More Promise for Climate Activity Stroke Trials Than NMDA Antagonists." Supplement I, Stroke 24:1148-1152, Ame		АН							
FOREIGN PATENT DOCUMENTS  EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLA  AL3 W0 99/12537 03/18/1999 WIPO  AM3 W0 99/26614 06/03/1999 WIPO  AN3 DE 198 02 327 A1 07/29/1999 Germany x  A03 W0 99/37296 07/29/1999 WIPO  AP3 W0 99/39712 08/12/1999 WIPO  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Brown, C.M., et al., "Neuroprotective properties of lifarizine compared with of other agents in a mouse model of focal cerebral ischaemia," Britis Pharmacol. 115:1425-1432, Stockton Press (1995)  Bryans, J.S., and Wustrow, D.J., "3-Substituted GABA Analogs with Central Ne System Activity: A Review," Med. Res. Rev. 19:149-177, John Wiley & Sons, (March 1999)  Buchan, A.M., et al., "AMPA Antagonists: Do They Hold More Promise for Clist Stroke Trials Than NMDA Antagonists: Do They Hold More Promise for Clist Stroke Trials Than NMDA Antagonists: Do They Hold More Promise for Clist Stroke Trials Than NMDA Antagonists: Do They Hold More Promise for Clist Stroke Trials Than NMDA Antagonists: Do They Hold More Promise for Clist Stroke Trials Than NMDA Antagonists: Do They Hold More Promise for Clist Stroke Trials Than NMDA Antagonists: Do They Hold More Promise for Clist Stroke Trials Than NMDA Antagonists? "Supplement I, Stroke 24:1148-1152, Ame		AI							
FOREIGN PATENT DOCUMENTS  EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLE  AL3 WO 99/12537 03/18/1999 WIPO  AM3 WO 99/26614 06/03/1999 WIPO  AN3 DE 198 02 327 A1 07/29/1999 WIPO  AP3 WO 99/37296 07/29/1999 WIPO  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Brown, C.M., et al., "Neuroprotective properties of lifarizine compared with of other agents in a mouse model of focal cerebral ischaemia," Britis Pharmacol. 115:1425-1432, Stockton Press (1995)  AS 3  Bryans, J.S., and Wustrow, D.J., "3-Substituted GABA Analogs with Central Ne System Activity: A Review," Med. Res. Rev. 19:149-177, John Wiley & Sons, (March 1999)  Buchan, A.M., et al., "AMPA Antagonists: Do They Hold More Promise for Climate and the stock of	•	AJ	1						
EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLI AL3 WO 99/12537 03/18/1999 WIPO  AM3 WO 99/26614 06/03/1999 WIPO  AN3 DE 198 02 327 A1 07/29/1999 Germany X  AO3 WO 99/37296 07/29/1999 WIPO  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Brown, C.M., et al., "Neuroprotective properties of lifarizine compared with of other agents in a mouse model of focal cerebral ischaemia," Britis Pharmacol. 115:1425-1432, Stockton Press (1995)  AS 3 Bryans, J.S., and Wustrow, D.J., "3-Substituted GABA Analogs with Central Ne System Activity: A Review," Med. Res. Rev. 19:149-177, John Wiley & Sons, (March 1999)  Buchan, A.M., et al., "AMPA Antagonists: Do They Hold More Promise for Climater and March 1999 Antagonists: Do They Hold More Promise for Climater and March 1999 Antagonists: Do They Hold More Promise for Climater and March 1999 Antagonists: Do They Hold More Promise for Climater and March 1999 Antagonists: Do They Hold More Promise for Climater and March 1999 Antagonists: Do They Hold More Promise for Climater and March 1999 Antagonists: Do They Hold More Promise for Climater and March 1999 Antagonists: Do They Hold More Promise for Climater and March 1999 Antagonists: Do They Hold More Promise for Climater and March 1999 Antagonists: Do They Hold More Promise for Climater and March 1999 Antagonists: Do They Hold More Promise for Climater and March 1999 Antagonists: Do They Hold More Promise for Climater and March 1999 Antagonists: Do They Hold More Promise for Climater and March 1999 Antagonists: Do They Hold More Promise for Climater and March 1999 Antagonists: Do They Hold More Promise for Climater and March 1999 Antagonists: Do They Hold More Promise for Climater and March 1999 Antagonists: Do They Hold More Promise for Climater and March 1999 Antagonists: Do They Hold More Promise for Climater and March 1999 Antagonists: Do They Hold More Promise for Climater and March 1999 Antagonists: Do They Hold More Promise for Climater and March 1999 Antagonists: Do They Hold More Promise		AK		<u> </u>					
INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLY  AL3 WO 99/12537 03/18/1999 WIPO  AM3 WO 99/26614 06/03/1999 WIPO  AN3 DE 198 02 327 A1 07/29/1999 Germany X  AO3 WO 99/37296 07/29/1999 WIPO  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Brown, C.M., et al., "Neuroprotective properties of lifarizine compared with of other agents in a mouse model of focal cerebral ischaemia," Britis Pharmacol. 115:1425-1432, Stockton Press (1995)  Bryans, J.S., and Wustrow, D.J., "3-Substituted GABA Analogs with Central Ne System Activity: A Review," Med. Res. Rev. 19:149-177, John Wiley & Sons, (March 1999)  Buchan, A.M., et al., "AMPA Antagonists: Do They Hold More Promise for Climatory Stroke Trials Than NMDA Antagonists: Do They Hold More Promise for Climatory Stroke Trials Than NMDA Antagonists?," Supplement I, Stroke 24:1148-1152, Ame.			•		FOREIGN P.	ATENT DOCUMENTS			-
AM3 WO 99/26614 06/03/1999 WIPO  AN3 DE 198 02 327 A1 07/29/1999 Germany X  AO3 WO 99/37296 07/29/1999 WIPO  AP3 WO 99/39712 08/12/1999 WIPO  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Brown, C.M., et al., "Neuroprotective properties of lifarizine compared with of other agents in a mouse model of focal cerebral ischaemia," Britis Pharmacol. 115:1425-1432, Stockton Press (1995)  AS 3 Bryans, J.S., and Wustrow, D.J., "3-Substituted GABA Analogs with Central Ne System Activity: A Review," Med. Res. Rev. 19:149-177, John Wiley & Sons, (March 1999)  Buchan, A.M., et al., "AMPA Antagonists: Do They Hold More Promise for Climate and Compared With Central Network of Compared With Central Net			DOCU	MENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AN3 DE 198 02 327 A1 07/29/1999 Germany  AO3 WO 99/37296 07/29/1999 WIPO  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Brown, C.M., et al., "Neuroprotective properties of lifarizine compared with of other agents in a mouse model of focal cerebral ischaemia," Britis Pharmacol. 115:1425-1432, Stockton Press (1995)  AS 3  Bryans, J.S., and Wustrow, D.J., "3-Substituted GABA Analogs with Central Ne System Activity: A Review," Med. Res. Rev. 19:149-177, John Wiley & Sons, (March 1999)  Buchan, A.M., et al., "AMPA Antagonists: Do They Hold More Promise for Climatory and Compared With Central Network of Compar		AL3	WO 9	9/12537	03/18/1999	WIPO			Yes No
AO3 WO 99/37296 07/29/1999 WIPO  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Brown, C.M., et al., "Neuroprotective properties of lifarizine compared with of other agents in a mouse model of focal cerebral ischaemia," Britis Pharmacol. 115:1425-1432, Stockton Press (1995)  Bryans, J.S., and Wustrow, D.J., "3-Substituted GABA Analogs with Central Ne System Activity: A Review," Med. Res. Rev. 19:149-177, John Wiley & Sons, (March 1999)  Buchan, A.M., et al., "AMPA Antagonists: Do They Hold More Promise for Climatory Stroke Trials Than NMDA Antagonists?," Supplement I, Stroke 24:1148-1152, American Stroke Trials Than NMDA Antagonists?," Supplement I, Stroke 24:1148-1152, American Stroke Trials Than NMDA Antagonists?," Supplement I, Stroke 24:1148-1152, American Stroke Trials Than NMDA Antagonists?," Supplement I, Stroke 24:1148-1152, American Stroke Trials Than NMDA Antagonists?		AM3	WO 9	9/26614	06/03/1999	WIPO .			Yes No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Brown, C.M., et al., "Neuroprotective properties of lifarizine compared with of other agents in a mouse model of focal cerebral ischaemia," Britis Pharmacol. 115:1425-1432, Stockton Press (1995)  Bryans, J.S., and Wustrow, D.J., "3-Substituted GABA Analogs with Central Ne System Activity: A Review," Med. Res. Rev. 19:149-177, John Wiley & Sons, (March 1999)  Buchan, A.M., et al., "AMPA Antagonists: Do They Hold More Promise for Climatory and Compared with the property of the		AN3	DE 1	.98 02 327 A1	07/29/1999	Germany			Yes X No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Brown, C.M., et al., "Neuroprotective properties of lifarizine compared with of other agents in a mouse model of focal cerebral ischaemia," Britis Pharmacol. 115:1425-1432, Stockton Press (1995)  Bryans, J.S., and Wustrow, D.J., "3-Substituted GABA Analogs with Central Ne System Activity: A Review," Med. Res. Rev. 19:149-177, John Wiley & Sons, (March 1999)  Buchan, A.M., et al., "AMPA Antagonists: Do They Hold More Promise for Climater and Stroke Trials Than NMDA Antagonists?," Supplement I, Stroke 24:1148-1152, American Stroke Trials Than NMDA Antagonists?," Supplement I, Stroke 24:1148-1152, American Stroke Trials Than NMDA Antagonists?		A03	WO 9	9/37296	07/29/1999	WIPO			Yes No
Brown, C.M., et al., "Neuroprotective properties of lifarizine compared with of other agents in a mouse model of focal cerebral ischaemia," Britis Pharmacol. 115:1425-1432, Stockton Press (1995)  Bryans, J.S., and Wustrow, D.J., "3-Substituted GABA Analogs with Central Ne. System Activity: A Review," Med. Res. Rev. 19:149-177, John Wiley & Sons, (March 1999)  Buchan, A.M., et al., "AMPA Antagonists: Do They Hold More Promise for Climater and the compared with the control of the compared with t		АРЗ	WO 9	9/39712	08/12/1999	WIPO			Yes No
AR 3 of other agents in a mouse model of focal cerebral ischaemia," Britis Pharmacol. 115:1425-1432, Stockton Press (1995)  Bryans, J.S., and Wustrow, D.J., "3-Substituted GABA Analogs with Central Ne System Activity: A Review," Med. Res. Rev. 19:149-177, John Wiley & Sons, (March 1999)  Buchan, A.M., et al., "AMPA Antagonists: Do They Hold More Promise for Climater and Stroke Trials Than NMDA Antagonists?," Supplement I, Stroke 24:I148-I152, American Americ			07	HER (Includin	g Author, Ti	tle, Date, Pertinent P	ages, etc	)	
AS 3 System Activity: A Review, " Med. Res. Rev. 19:149-177, John Wiley & Sons, (March 1999)  Buchan, A.M., et al., "AMPA Antagonists: Do They Hold More Promise for Climate Stroke Trials Than NMDA Antagonists?," Supplement I, Stroke 24:I148-I152, American									
AT 3 Stroke Trials Than NMDA Antagonists?," Supplement I, Stroke 24:I148-I152, Ame.								ntral Nervous & Sons, Inc.	
	=							for Clinical 152, American	
EXAMINER DATE CONSIDERED	EXAMINER	1	1	1	<u> </u>		DATE	CONSIDERED	

<sup>::</sup>ODMA\MHODMA\SKGF\_DC1;197764;1



## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783				
APPLICANT Nancy C. LAN					
FILING DATE August 21, 2003	GROUP				

					August 21, 2003		1614	
				U.S. PAT	ENT DOCUMENTS			
EXAMINER								
INITIAL		DOCU	MENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA	+						
	AB			ļ				
	AC	+		<u> </u>				<del> </del>
	AD AE					-		
•	AF	.		<del> </del>			<u> </u>	<del> </del>
	AG	<del></del>				<del>                                     </del>		<del>                                     </del>
<u>-</u>	AH	+						<del></del>
	AI	<del> </del>		<u> </u>				
	AJ	<del> </del>		\				
	AK	1				-	<u> </u>	-
<del></del>	AK			POPETCH D	ATENT DOCUMENTS	<u>l</u>	1	<del></del>
EXAMINER		I		FOREIGN P	ATENT DOCUMENTS	T	I	T
INITIAL		DOCU	MENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	ļ							Yes
	AL4	WO 9	9/44610	09/10/1999	WIPO	ļ		N <sub>0</sub>
	AM4	WO 9	9/61408	12/02/1999	WIPO			X Yes
	Alif	1 10 3	27 01400	12/02/1333	WIFO			Ye
	AN4	wo o	0/02562	01/20/2000	WIPO			No
								Yes
	A04	WO 0	0/02592	01/20/2000	WIPO	_		No
	AP4	WO 0	0/57877	10/05/2000	WIPO			Yes
	1					ges etc	. \	
	OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  AR  4  Canavero, S., et al., "The riddle of trigeminal neuralgia," Pain 60:229-2 Elsevier Science B.V. (1995)						1 60:229-231	
	AS	Carrazana, E.J., and Schachter, S.C., "Alternative uses of lamotrigine and gabapentin in the treatment of trigeminal neuralgia," Neurology 50:1192, The American Academy of Neurology (April 1998)						
Catterall, W.A., "Common modes of drug action on Na+ channels: local anestheti antiarrhythmics and anticonvulsants," <i>Trends Pharmacol. Sci. 8</i> :57-65, Elsev Science Publishers B.V. (1987)								
EXAMINER	<u> </u>	1	I			DATE	CONSIDERED	

<sup>::</sup>ODMA\MHODMA\SKGF\_DC1;197764;1



## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE	GROUP

EXAMINER		r		U.S. PAT	ENT DOCUMENTS			
EXAMINER								
INITIAL		DOCU	MENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA							
	AB							
	AC				_			
	AD							
	AE							
	AF							
	AG					_		
	AH							
	AI						_	
	AJ							
	AK							
				FOREIGN PA	ATENT DOCUMENTS			
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
								Yes
	AL5	EP 1	083 164	03/14/2001	Europe			No
	AM							Yes · No
	AN							Yes No
		_						Yes
	AO							No Yes
	AP							No.
	—-г	OT	HER (Including	Author, Tit	le, Date, Pertinent Page	es, etc	.)	
P	Catterall, W.A., "Neurotoxins That Act on Voltage-sensitive Sodium Channels in Excitable Membranes," Ann. Rev. Pharmacol. Toxicol. 20:15-43, Annual Reviews Inc. (1980)							
P	AS	<u>5</u>	Catterall, W.A., "Structure and Function of Voltage-Sensitive Ion Channels," Science 242:50-61, The American Association for the Advancement of the Science (1988)					
A	AТ	Chapman, V., et al., "Effects of systemic carbamazepine and gabapentin on spinal neuronal responses in spinal nerve ligated rats," Pain 75:261-272, Elsevier Science B.V. (April 1998)						
EXAMINER						DATE C	CONSIDERED	

<sup>::</sup>ODMA\MHODMA\SKGF\_DC1;197764;1



CIPE C	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
RADE MADE	<i>]</i>

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE	GROUP

August 21, 2003   1614								
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA							
	AB							
	AC							
	AD							
	AE							
	AF							
	AG							
*	АН							
	AI							
-	AJ							
	AK							
				FOREIGN PA	ATENT DOCUMENTS			
EXAMINER								
INITIAL	<del> </del>	DOCU	MENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL							Yes No
	AM							Yes No
	AN							Yes No
								Yes
	AO							No Yes
	AP							No
		ro	THER (Including	g Author, Tit	tle, Date, Pertinent Pag	es, etc	.)	
								n from Guinea
	AS	<u>6</u>	Czuczwar, S.J., and Przesmycki, K., "Felbamate, Gabapentin and Topiramate as Adjuvant Antiepileptic Drugs in Experimental Models of Epilepsy," Polish J. Pharmacol. 53:65-68, Polish Academy of Sciences (2001)					
	AT	<u>6</u>	De Sarro, G., et al., "Gabapentin Potentiates the Antiseizure Activity of Certain Anticonvulsants in DBA/2 Mice," Eur. J. Pharmacol. 349:179-185, Elsevier Science (1998)					
EXAMINER						DATE (	CONSIDERED	



10	,	~	3
	25	M	2
L'an			
WAY.			<u> </u>
100	PAAD	E	

FORM	PTO-	14	49

#### INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE August 21, 2003	GROUP 1614

U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA							
	AB					1		
	AC							
	AD							
	AE					-		
•	AF	<u> </u>						
	AG							
•	АН							
	AI						-	
•	AJ						· · · · · · · · · · · · · · · · · · ·	-
	AK							
	<u>*</u>			FOREIGN PA	ATENT DOCUMENTS	<del></del>		
EXAMINER								
INITIAL		DOCU	MENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL							Yes No
	AM		,					Yes No
	AN		*****					Yes
	AN							No
	AO							Yes No
	AP	j						Yes No
	1 ***	ОТ	HER (Including	Author Tit	le Date Pertinent Dag	es etc	```	NO
:	OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Denicoff, K.D., et al., "Efficacy of Carbamazepine Compared With Other Agents: AR 7 Clinical Practice Survey," J. Clin. Psychiatry 55:70-76, Physicians Postgraduate Press, Inc. (1994)							er Agents: A Postgraduate
	AS	<u>7</u>	Dichter, M.A., et al., "Drug Therapy: New Antiepileptic Drugs," New Engl. J. Med. 334:1583-1590, Massachusetts Medical Society (1996)					
	AT	7	Field, M.J., et al., "Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat," Pain 80:391-398, Elsevier Science B.V. (March 1999)					
EXAMINER DATE CONSIDERED								



## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783				
APPLICANT Nancy C. LAN					
FILING DATE August 21, 2003	GROUP 1614				

				U.S. PAT	TENT DOCUMENTS			
EXAMINER	1	Τ		1		T		
INITIAL	ļ	DOCU	MENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA	ļ						
	AB	<u> </u>	<u></u>					
	AC	<u> </u>						
	AD							
	AE							
	AF			ļ				
	AG	<u> </u>						
	HA	<b>.</b>						
	AI	-						
	AJ					<u> </u>		
	AK	ŀ		<u> </u>	<u> </u>	<u> </u>		l
	T	1		FOREIGN P.	ATENT DOCUMENTS	1	-	r
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
								Yes
	AL	-						No
	AM							Yes No
	AN							Yes No
	AO							Yes No
·- · · · · · ·	AP							Yes
	IAP				l Park Parkings Parkings		`	No
	T	01	HER (INCIDEIN	g Author, Ti	tle, Date, Pertinent Pag	es, etc	.)	
·	AR B Goldberg, I., and Green, B., "Focus on Gabapentin," Focus 8:1-6, Priory Lodge Education Ltd. (1997) from http://www.priory.com/focus8.htm							
	AS	<u>8</u>	Graham, S.H., et al., "A Dose-Response Study of Neuroprotection Using the AMPA Antagonist NBQX in Rat Focal Cerebral Ischemia," J. Pharmacol. Exp. Therap. 276:1-4, Williams & Wilkins (1996)					
	Graham, S.H., et al., "Neuroprotective Effects of a Use-Dependent Blocker of Voltage-Dependent Sodium Channels, BW619C89, in Rat Middle Cerebral Artery Occlusion," J. Pharmacol. Exp. Therp. 269:854-859, Williams & Wilkins (1994)							
EXAMINER		<u> </u>				DATE (	CONSIDERED	
EXAMINER: I	nitial	if re	eference consi	dered, wheth	er or not citation is in	confor	mance with	MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
::ODMA\MHODMA\SKGF\_DC1;197764;1



ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE August 21, 2003	GROUP 1614

				U.S. PA	TENT DOCUMENTS			
EXAMINER INITIAL		DOC	UMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
<u> </u>	AA							
	AB							
	AC							
	AD							
	AE							
	AF	<u> </u>						
-	AG							
	AH							
	AI	ļ						
	AJ	<u> </u>		ļ				
	AK							
-		_		FOREIGN E	PATENT DOCUMENTS			_
EXAMINER INITIAL			IMENIO NUMBER	DA WE	COUNTRY	07.7.05	GUD 67.366	mp.),;g= -====
INITIAL		DOC	JMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL							Yes No
	АМ							Yes No
	AN							Yes
<u>-</u>								No Yes
	AO							No Yes
	AP						<u>.</u>	No
	1	0:	THER (Includin	g Author, Ti	tle, Date, Pertinent	Pages, etc	.)	
	Gurney, et al., "Benefit of Vitamin E, Riluzole, and Gabapentin in a Transgenic Model of Familial Amyotrophic Lateral Sclerosis," Ann. Neurol. 39:147-157, The American Neurological Association (1996)							a Transgenic 147-157, The
	AS	<u>9</u>	Hamill, O.P., et al., "Improved Patch-Clamp Techniques for High-Resolution Current Recording from Cells and Cell-Free Membrane Patches," Pfluegers Arch 391:85-100, Springer International (1981)					
	Hoekstra, M.S., et al., "Chemical Development of CI-1008, an Enantiomerically Pure Anticonvulsant," Org. Process Res. Dev. 1:26-38, American Chemical Society and Royal Society of Chemistry (1997)							erically Pure Society and
EXAMINER	1 .	1	<u> </u>			DATE (	CONSIDERED	<del>-</del>
EXAMINER: Draw line t next commun ::ODMA\MHODM	hrough ication	citat:   to A	ion if not in pplicant.	dered, wheth	ner or not citation is and not considered.	in confor Include co	mance with py of this	MPEP 609. form with



ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE	GROUP

				υ.s.	PATENT DOCUMENTS			
EXAMINER INITIAL		DOC	UMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA			<u> </u>				
	AB							
	AC						<u> </u>	
	AD	<b></b>						<b>_</b>
	AE			<u> </u>				
	AF							
	AG	-		<del>-</del>				
	AH	-		<u> </u>				-
	AI	-					<del>                                     </del>	
	AJ	-		<u> </u>				<del> </del>
	AK							
		т—		FOREIGN	V PATENT DOCUMENTS		T	<u> </u>
EXAMINER INITIAL		DOC	UMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL							Yes
	AM							Yes
	AN							Yes
	AO							Yes
	AP							Yes
	1		THER (Includir	a Author	Title, Date, Perti	Pages etc	. \	1 100
	AR	10	Hunskaar, S.	, et al.,	"Formalin test in eurosci. Methods 14	mice, a useful	technique fo	
	AS	10	Iwasaki, Y., et al., "CNQX prevents spinal motor neuron death following sciation nerve transection in newborn rats," J. Neuro Sci. 134:21-25, Elsevier Science B.V. (1995)					
			Vim S H o	t al "An	evnerimental mode	l for periphera	l neuropath	
	AT	10		inal nerve	e ligation in the :			



ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE	GROUP

U.S. PATENT DOCUMENTS									
EXAMINER		Pog	TATING MINDED	D. WE		GT 100	aven av vaa	DILLING DAME	
INITIAL	AA	DOC	UMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE	
	AB					<u> </u>			
	AC	<b>†</b>							
	AD								
•	AE								
	AF		,						
•	AG					<u></u>			
	AH								
	AI					ļ	<b></b>		
	AJ					<u> </u>			
	AK					<u> </u>			
	- T	1		FOREIGN P.	ATENT DOCUMENTS		T	T	
EXAMINER INITIAL		DOCT	JMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
	AL							Yes	
	AL	+						No Yes	
	AM							No.	
	AN							Yes No	
	AO							Yes No	
								Yes	
	AP					<u> </u>	<u> </u>	No	
	1	T	THER (Includin	g Author, Ti	tle, Date, Pertinent Pag	jes, etc	.)		
	AR	11		pain and comp	al review of controlled lex regional pain syndro				
	Kudoh, A., et al., "Effect of Carbamazepine on Pain Scores of Unipolar Depresse  AS 11 Patients with Chronic Pain: A Trial of Off-On-Off-On Design," Clin. J. Pain 14:61 65, Lippincott-Raven Publishers (1998)								
	AT 11 Low, P.A., and Dotson, R.M., "Symptomatic Treatment of Painful Neuropathy," JAMP 280:1863-1864, The American Medical Association (December 1998)								
EXAMINER	•		· · · · · · · · · · · · · · · · · · ·			DATE (	CONSIDERED		
EXAMINER: Draw line to next commune::ODMA\MHODM	hrough ication	citat 1 to A	ion if not in pplicant.	dered, wheth conformance	er or not citation is in and not considered. Ind	n confor clude co	mance with	MPEP 609. form with	



ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE	GROUP

				U.S. I	PATENT DOCUMENTS					
EXAMINER INITIAL		DOC	UMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE		
	AA									
	AB									
	AC									
	AD									
•	AE		·							
	AF									
•	AG									
	AH									
	AI	<u> </u>								
	AJ									
	AK			<u></u>				<u> </u>		
				FOREIGN	PATENT DOCUMENTS	<del></del>				
EXAMINER INITIAL		DOC!	UMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION		
INITIAL	-	DOC	UMENI NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	Yes		
	AL							No		
	7.14							Yes		
	AM	<u> </u>						No		
	AN							Yes No		
	1,,							Yes		
	AO							No Yes		
	AP						<u></u>	No.		
		0	THER (Includin	g Author,	Title, Date, Pertin	nent Pages, etc	:.)			
	AR	12	Lunardi, G., essential a Lippincott-R	nd sympton	Clinical effectivene matic trigeminal shers (1997)	ess of lamotrion neuralgia,"	gine and pla Neurology	sma levels in 48:1714-1717,		
	AS 12 Magnus, L., "Nonepileptic Uses of Gabapentin," Epilepsia 40(Suppl. 6):S66-S7 Lippincott Williams & Wilkins (October 1999)									
	AT 12 Nicholson, B., "Gabapentin use in neuropathic pain syndromes," Dolor 14:243-250 Publicaciones Permanyer (1999)									
EXAMINER		1,	<u> </u>			DATE	CONSIDERED			
EXAMINER: Draw line to next communation:	hrough	citat ı to A	ion if not in pplicant.	dered, whe	ther or not citation e and not considere	on is in conformation of the conformation of t	rmance with opy of this	MPEP 609. form with		



ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE	GROUP

				U.S. PA	ATENT DOCUMENTS				
EXAMINER INITIAL	_	DOC	UMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE	
	AA							ļ <u>.</u>	
	AB	-		<b>_</b>					
	AC			ļ					
•	AD								
•	AE	<del></del> -							
	AF	_					ļ <u> </u>		
•	AG								
	AH						<b> </b>		
,	AI	+							
· · · · · · · · · · · · · · · · · · ·	AJ	-							
	AK	1							
	I			FOREIGN	PATENT DOCUMENTS		T	T	
EXAMINER INITIAL		DOC	UMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
	AL							Yes	
								Yes	
	AM	<del>                                     </del>						No.	
	AN	<u> </u>						No	
	AO	<u> </u>						Yes No	
	AP							Yes No	
		0'	THER (Includin	g Author, T	itle, Date, Pertinen	it Pages, etc	.)		
•	AR	13	Muscle Sodiu	m Channels b	pecific Inhibitors of Geographutoxin II 52, The American So	, a Polypept	ide Channel	Blocker, " J	
	AS	Rosenberg, J.M., et al., "The Effect of Gabapentin on Neuropathic Pain," Clin. J. Pain 13:251-255, Lippincott-Raven Publishers (1997)							
	AT 13 Rosner, H., et al., "Gabapentin Adjunctive Therapy in Neuropathic Pain States,"  Clin. J. Pain 12:56-58, Lippincott-Raven Publishers (1996)								
EXAMINER	1	.1				DATE (	CONSIDERED		
EXAMINER: IDraw line the next communi	rough cation	citat to A	ion if not in pplicant.	dered, whet conformance	her or not citation and not considered.	is in confor	rmance with opy of this	MPEP 609. form with	



ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE	GROUP

				<b>U.S.</b>	PATENT DOCUMENTS				
EXAMINER INITIAL		DOCU	JMENT NUMBER	DATE	NAME		CLASS	SUB-CLASS	FILING DATE
	AA								
	AB								
	AC	ļ							
	AD								
•	AE								
	AF	<u> </u>							
	AG	<u> </u>							
	AH	_							
<del></del>	AI	_							
	AJ	_							
	AK		···	<u> </u>					
				FOREIG	N PATENT DOCUMENT	:s			
EXAMINER		DOG!	DATE STATE	D. W.D.	COLDINA		CT ACC	CITE CLASC	EDANCE ACTOM
INITIAL		DOCE	JMENT NUMBER	DATE	COUNTRY		CLASS	SUB-CLASS	TRANSLATION
	AL								Yes No
	AM								Yes No
	AN								Yes No
	720	1							Yes
	AO	-							No Yes
··	AP								No
		0'	THER (Includin	g Author,	Title, Date, Per	tinent Page	s, etc	:.)	
	AR	14			"Gabapentin for ne American Medic				
	AS	14	Sheardown, M.J., et al., "AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischaemia, even when delayed 24 h," Eur. J. Pharmacol. 236:347-353, Elsevier Science Publishers B.V. (1993)						
	AT	14		port of Te	experience With Ga n Cases," Reg. Ar 1997)				
EXAMINER	<u> </u>		<u> </u>				DATE	CONSIDERED	
EXAMINER:	Initia	l if r	eference cons	idered, wh	ether or not cita	ation is in	confo	rmance with	MPEP 609.
	through	citat	ion if not in		ce and not consid				
:ODMA\MHOD	MA\SKGF	DC1;1	.97764;1						





## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE	GROUP

U.S. PATENT DOCUMENTS									
EXAMINER INITIAL		DOCT	JMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE	
	AA								
	AB								
	AC	<u> </u>							
	AD								
•	AE	ļ							
	AF								
	AG	<u> </u>							
	AH	4				1			
,	AI	-							
-	AJ	<b>-</b>							
<del>un</del>	AK	<u> </u>		<u></u>					
•			······································	FOREIGN P.	ATENT DOCUMENTS	1	1	1	
EXAMINER INITIAL		DOCU	JMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
	AL							Yes No	
								Yes	
	AM							No Yes	
	AN					<u> </u>		No	
	AO	ļ						Yes No	
	AP							Yes No	
		o:	THER (Includin	g Author, Ti	tle, Date, Pertinent Pa	ges, etc	.)		
	AR	<u>15</u>	Solaro, C., a rare paro: Williams & W:	xysmal sympt	atient with multiple sc om at onset," <i>Eur. J.</i> 1999)	lerosis Neurol	and Down's s	syndrome with , Lippincott	
	Stys, P.K., et al., "Ionic Mechanisms of Anoxic Injury in Mammalian CNS White Matter: Role of Na* Channels and Na*—Ca²* Exchanger," J. Neurosci. 12:430-439, Society for Neuroscience (1992)								
	AT 15 Taylor, C.P., et al., "Na+ channels as targets for neuroprotective drugs," Trends Pharmacol. Sci. 16:309-316, Elsevier Science Ltd. (1995)								
EXAMINER	•	•	•		- Harris 1997	DATE (	CONSIDERED		
EXAMINER:	EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.								

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
::ODMA\MHODMA\SKGF\_DC1;197764;1

Page 16 of 20 ATTY. DOCKET NO. APPLICATION NO. 10/644,783 1483.0370003/JMC/THN FORM PTO-1449 APPLICANT Nancy C. LAN INFORMATION DISCLOSURE STATEMENT FILING DATE GROUP August 21, 2003 1614 U.S. PATENT DOCUMENTS EXAMINER DOCUMENT NUMBER DATE NAME CLASS SUB-CLASS FILING DATE INITIAL AΑ AB AC AD ΑE AF AG AΗ ΑI ΑJ ΑK FOREIGN PATENT DOCUMENTS EXAMINER DOCUMENT NUMBER CLASS SUB-CLASS DATE COUNTRY TRANSLATION INITIAL Yes ALNo Yes ΑM No Yes AN No Yes No ΑO Yes ΑP No OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Verdoorn, T.A., et al., "Functional Properties of Recombinant Rat GABA, Receptors AR 16 Depend upon Subunit Composition, " Neuron 4:919-928, Cell Press (1990) Victor, M., et al., "Chapter 352: Diseases of the Cranial Nerves," in Harrison's AS Principles of Internal Medicine 11:2035-2040, Braunwald, et al., eds., McGraw-Hill <u>16</u> Inc. (1987) 

EXAMINER DATE CONSIDERED

Elsevier Science B.V. (1994)


**EXAMINER**: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

potential firing by mouse central neurons in cell culture," Epilepsy Res. 17:1-11,

ΑT

<u>16</u>

<sup>::</sup>ODMA\MHODMA\SKGF\_DC1;197764;1



<i>(</i>	OIPER	
(	NOV 2 5 2003 =	
1 Co		
	TRADEN	

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE	GROUP

August 21, 2003   1614									
U.S. PATENT DOCUMENTS									
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE	
	AA								
	AB								
	AC					-			
	AD								
	AE								
	AF		., .,,						
	AG								
•	AH								
	AI								
	AJ								
	AK								
				FOREIGN P.	ATENT DOCUMENTS				
EXAMINER									
INITIAL	<u> </u>	DOCU	MENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
	AL	ļ						Yes No	
	AM							Yes No	
	AN							Yes No	
						1-1-		Yes	
	AO							No Yes	
	AP							No	
		ro	HER (Includin	g Author, Ti	tle, Date, Pertinent Pag	es, etc	.)		
	AR	<u>17</u>	Trauma with	Systemically	"Amelioration of Functi Administered NBQX, an D. Neurology 137:119-126	Antago	nist of Nor	n-N-methyl-D-	
	AS	<u>17</u>	Yoon, M.H., and Yaksh, T.L., "Evaluation of Interaction between Gabapentin and Ibuprofen on the Formalin Test in Rats," <i>Anesthesiology 91</i> :1006-1013, Lippincott Williams & Wilkins, Inc. (October 1999)						
	АТ	<u>17</u>	Dialog File 3 DE 198 02 32	51, Accession 7 Al (Documen	n No. 12613976, Derwent W nt AN3)			abstract for	
EXAMINER						DATE	CONSIDERED		



INFORMATION	DISCLOSURE	STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783				
APPLICANT Nancy C. LAN					
FILING DATE August 21, 2003	GROUP 1614				

AA AB A	<u> </u>					August 21, 2003		1614	
INITIAL					U.S. PAT	TENT DOCUMENTS			
AA AB AB AC ACCESSION NO. 1998:9096, "Warner-Lambert forecasts 35% ears			DOC	UMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AC AD AD AB AE AC AF AF AG AG AD AD AH AI		AA					1		
AD AE AE AF AG AG AH AI AI AI AI AK  COUNTRY CLASS SUB-CLASS TRANSLA AL AM AN		AB							
AE AF AG AG AG AH AI AI AI AI AI AX AX FOREIGN PATENT DOCUMENTS  EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLA AM AN AN AN AO AD AP OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  AR 18 List of abstracts concerning SCRIP 1773:14 (1992) provided by client  AS 18 List of abstracts concerning SCRIP 1870:8 (1993) provided by client  AT 18 STN Database, Accession No. 1998:9096, "Warner-Lambert forecasts 35% earn growth," SCRIP 2330:8 (1998)		AC							
AF AG AG AI		AD							
AF AG AH AI		AE							
AI A	•	AF							
AI AJ AK FOREIGN PATENT DOCUMENTS  EXAMINER INITIAL AL AM AN AN AN AN AN AN AN AN AP OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  AR 18 List of abstracts concerning SCRIP 1773:14 (1992) provided by client  AS 18 List of abstracts concerning SCRIP 1870:8 (1993) provided by client  AT 18 STN Database, Accession No. 1998:9096, "Warner-Lambert forecasts 35% earn growth," SCRIP 2330:8 (1998)		AG							
FOREIGN PATENT DOCUMENTS  EXAMINER INITIAL  AL  AM  AN  AO  AP  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  AR  AR  AR  AR  AR  AR  AR  AR  AR  A		АН							
EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLA AL AN AN AN AN AN AN AP OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  AR 18 List of abstracts concerning SCRIP 1773:14 (1992) provided by client  AS 18 List of abstracts concerning SCRIP 1870:8 (1993) provided by client  AT 18 STN Database, Accession No. 1998:9096, "Warner-Lambert forecasts 35% earn growth," SCRIP 2330:8 (1998)		AI							
EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLA AL AM AN AN AO AP OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  AR 18 List of abstracts concerning SCRIP 1773:14 (1992) provided by client  AS 18 List of abstracts concerning SCRIP 1870:8 (1993) provided by client  AT 18 STN Database, Accession No. 1998:9096, "Warner-Lambert forecasts 35% earn growth," SCRIP 2330:8 (1998)	•	AJ							
EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLA AL AM AM AN AO AP OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  AR 18 List of abstracts concerning SCRIP 1773:14 (1992) provided by client  AS 18 List of abstracts concerning SCRIP 1870:8 (1993) provided by client  AT 18 STN Database, Accession No. 1998:9096, "Warner-Lambert forecasts 35% earn growth," SCRIP 2330:8 (1998)	*	AK							
AL  ADOCUMENT NUMBER DATE COUNTRY  AL  AL  AM  AN  AN  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  AR  AR  AB  List of abstracts concerning SCRIP 1773:14 (1992) provided by client  AS  AS  AS  AS  AS  AS  AS  AS  AS  A					FOREIGN P.	ATENT DOCUMENTS	•		·
AM  AN  AN  AO  AP  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  AR  AR  AR  AR  AB  List of abstracts concerning SCRIP 1773:14 (1992) provided by client  AS  AS  AS  AS  AS  AS  AS  AS  AS  A			DOC	UMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AN  AO  AP  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  AR  18  List of abstracts concerning SCRIP 1773:14 (1992) provided by client  AS  18  List of abstracts concerning SCRIP 1870:8 (1993) provided by client  AT  18  STN Database, Accession No. 1998:9096, "Warner-Lambert forecasts 35% earn growth," SCRIP 2330:8 (1998)		AL							Yes
AP  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  AR  18  List of abstracts concerning SCRIP 1773:14 (1992) provided by client  AS  18  List of abstracts concerning SCRIP 1870:8 (1993) provided by client  AT  18  STN Database, Accession No. 1998:9096, "Warner-Lambert forecasts 35% earn growth," SCRIP 2330:8 (1998)		AM							Yes No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  AR 18 List of abstracts concerning SCRIP 1773:14 (1992) provided by client  AS 18 List of abstracts concerning SCRIP 1870:8 (1993) provided by client  AT 18 STN Database, Accession No. 1998:9096, "Warner-Lambert forecasts 35% earn growth," SCRIP 2330:8 (1998)		AN							Yes No
AR 18 List of abstracts concerning SCRIP 1773:14 (1992) provided by client  AS 18 List of abstracts concerning SCRIP 1870:8 (1993) provided by client  AT 18 STN Database, Accession No. 1998:9096, "Warner-Lambert forecasts 35% earn growth," SCRIP 2330:8 (1998)		AO							Yes No
AR 18 List of abstracts concerning SCRIP 1773:14 (1992) provided by client  AS 18 List of abstracts concerning SCRIP 1870:8 (1993) provided by client  AT 18 STN Database, Accession No. 1998:9096, "Warner-Lambert forecasts 35% earn growth," SCRIP 2330:8 (1998)	<u> </u>	AP			_				Yes No
AR 18 List of abstracts concerning SCRIP 1773:14 (1992) provided by client  AS 18 List of abstracts concerning SCRIP 1870:8 (1993) provided by client  AT 18 STN Database, Accession No. 1998:9096, "Warner-Lambert forecasts 35% earn growth," SCRIP 2330:8 (1998)			0'	THER (Includin	g Author, Ti	tle, Date, Pertinent Pag	es, etc	.)	
AT 18 STN Database, Accession No. 1998:9096, "Warner-Lambert forecasts 35% earn growth," SCRIP 2330:8 (1998)	. <u>.</u>	AR	18	List of abst	racts concern	ning SCRIP 1773:14 (1992	) provic	ded by clier	nt
growth, " SCRIP 2330:8 (1998)		AS	18	List of abst	acts concern	ning SCRIP 1870:8 (1993)	provide	ed by client	:
EXAMINER DATE CONSIDERED		AT	18	STN Database growth," SCRI	, Accession IP 2330:8 (19	No. 1998:9096, "Warner- 98)	Lambert	forecasts	35% earnings
	EXAMINER		1	<u> </u>			DATE O	CONSIDERED	

<sup>::</sup>ODMA\MHODMA\SKGF\_DC1;197764;1




· FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783			
APPLICANT Nancy C. LAN				
FILING DATE August 21, 2003	GROUP			

					August 21, 2003	:	1614	
				U.S. PA	TENT DOCUMENTS			
EXAMINER INITIAL		DOC	UMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA							
	AB							
	AC							
	AD							
	AE							
•	AF							<u> </u>
	AG				<u></u>			
	AH							
	AI			<u> </u>				
<u> </u>	AJ							<u> </u>
	AK							
				FOREIGN F	ATENT DOCUMENTS			
EXAMINER INITIAL		DOC	UMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATIO
	AL							Ye N
	AM							Ye N
								Ye
	AN	+		<u> </u>				N Ye
	OA			<u> </u>				N
	AP				<u></u>			Ye N
		0'	THER (Includin	ng Author, Ti	tle, Date, Pertinent	Pages, etc	:.)	
	AR	19	United State	s Application	n No. 60/126,553, Hoge	nkamp et a	al., filed Ma	arch 26, 199
	AS	<u>19</u>			c drugs in the treatme 206, Future Drugs Ltd.		opathic pair	n," <i>Exp</i> . Rev
	AT	19	Bennett, G.J	J., "Neuropat	thic Pain: New Insigh 4,107-110,113-114, The	nts, New I	Intervention	s," Hospita
			riactice 33.1	75 70,101 10-	1,107-110,113-114, The	coraw mr	rr companies	s, inc. (1996

<sup>::</sup>ODMA\MHODMA\SKGF\_DC1;197764;1



DIPE 101 2 5 2003
TRADENAM

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE	GROUP

August 21, 2003   1614								
U.S. PATENT DOCUMENTS								
EXAMINER								
INITIAL	<b> </b>	DOCU	MENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA	<del>-</del>				-		
	AB AC	1	<del></del>	<u> </u>				
	AD	<del> </del>						
	AE	-	<del></del>					
	AF	1						
	AG	<b>†</b>						
	АН	1						
	AI							
	AJ							
•	AK							
				FOREIGN PA	ATENT DOCUMENTS			
<b>EXAMINER</b>					(-			
INITIAL	-	DOCU	MENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL							Yes No
	AM			i				Yes No:
	AN							Yes
	AN	<u> </u>						No Yes
	AO							No Ya a
	AP							Yes No
		ОТ	HER (Including	g Author, Tit	tle, Date, Pertinent Pag	es, etc	.)	
	Borowicz, K.K., et al., "Effect of Gabapentin on the Anticonvulsant Activity of Antiepileptic Drugs against Electroconvulsions in Mice: An Isobolographic Analysis," Epilepsia 43:956-963, Blackwell Publishing, Inc. (2002)							: Activity of sobolographic
	AS							
EVAMINED	AT					T		
EXAMINER						DATE	CONSIDERED	